Highlights
- •Irisin levels were significantly elevated after CSII treatment in T2DM patients.
- •Elevated irisin was accompanied by improved glycemic control and lipid profiles.
- •Elevated irisin may represent benefits of ameliorative metabolism following CSII.
Abstract
Irisin, identified as a novel myokine, plays an important role in improving metabolic
disorders, including type 2 diabetes mellitus (T2DM). In this interventional study,
we investigated the alteration of serum irisin levels in T2DM subjects after transient
continuous subcutaneous insulin infusion (CSII) treatment.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Diabetes Research and Clinical PracticeAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Muscles, exercise and obesity: skeletal muscle as a secretory organ.Nat Rev Endocrinol. 2012; 8: 457-465https://doi.org/10.1038/nrendo.2012.49
- Muscles and their myokines.J Exp Biol. 2011; 214: 337-346https://doi.org/10.1242/jeb.048074
- A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.Nature. 2012; 481: 463-468https://doi.org/10.1038/nature10777
- Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling.Diabetes. 2014; 63: 514-525https://doi.org/10.2337/db13-1106
- Adipose tissue browning and metabolic health.Nat Rev Endocrinol. 2014; 10: 24-36https://doi.org/10.1038/nrendo.2013.204
- Serum irisin levels in new-onset type 2 diabetes.Diabetes Res Clin Pract. 2013; 100: 96-101https://doi.org/10.1016/j.diabres.2013.01.007
- Lower circulating irisin is associated with type 2 diabetes mellitus.J Diabetes Complicat. 2013; 27: 365-369https://doi.org/10.1016/j.jdiacomp.2013.03.002
- Circulating irisin in relation to insulin resistance and the metabolic syndrome.J Clin Endocrinol Metab. 2013; 98: 4899-4907https://doi.org/10.1210/jc. 2013-2373
- Lower irisin level in patients with type 2 diabetes mellitus: a case-control study and meta-analysis.J Diabetes. 2014; https://doi.org/10.1111/1753-0407.12256
- Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.Lancet. 2008; 371: 1753-1760https://doi.org/10.1016/S0140-6736(08)60762-X
- Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function.Diabetes Obes Metab. 2012; 14: 161-166https://doi.org/10.1111/j. 1463-1326.2012.01658.x
- The effect of improved diabetic control on plasma lipid and lipoprotein levels: a comparison of conventional therapy and continuous subcutaneous insulin infusion.Diabetes. 1980; 29: 1001-1005
- Observations on blood lipid and intermediary metabolite concentrations during conventional insulin treatment or CSII.Diabetes. 1985; 34: 27-30
- Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus.Metabolism. 1991; 40: 445-449
- Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes.Clin Sci (Lond). 2015; 129: 839-850https://doi.org/10.1042/CS20150009
- Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway.Int J Obes (Lond). 2015; https://doi.org/10.1038/ijo.2015.199
- FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity.Biochim Biophys Acta. 2015; 1852: 1867-1875https://doi.org/10.1016/j.bbadis.2015.06.017
- PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes.Diabetologia. 2006; 49: 1477-1488https://doi.org/10.1007/s00125-006-0268-6
- PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.Nat Genet. 2003; 34: 267-273https://doi.org/10.1038/ng1180
- Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1.Proc Natl Acad Sci USA. 2003; 100: 8466-8471https://doi.org/10.1073/pnas.1032913100
Article info
Publication history
Published online: January 30, 2016
Accepted:
January 22,
2016
Received in revised form:
January 17,
2016
Received:
August 13,
2015
Identification
Copyright
© 2016 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
